Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida

References

• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, : Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005;307:380-4
   PubMed Web of Science ®Google Scholar
• Standl E. The importance of beta-cell management in type 2 diabetes. Int J Clin Pract Suppl 2007;153:10-19
   Google Scholar
• Inzucchi SE, Majumdar SK. Current therapies for the medical management of diabetes. Obstet Gynecol 2016;127:780-94
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the US, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
   Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocrine Pract 2015;21(Suppl1):1-87
   Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2015;38(Suppl1):S1-S94
   Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20:S53-S8
   PubMed Web of Science ®Google Scholar
• Lafeuille M, Grittner AM, Gravel JH. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care 2014;20(1Suppl):S5-S15
   Web of Science ®Google Scholar
• Lafeuille M, Grittner AM, Gravel JH. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. J Med Econ 2015;18:113-25
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance. HEDIS. NCQA; 2016 Available online at: http://www.ncqa.org/programs/accreditation/disease-management-dm/dm-performance-measures. Accessed February 6, 2018
   Google Scholar
• Bailey RA, Vijapurkar U, Meininger GE. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care 2014;20(13Suppl):S296-S305
   Web of Science ®Google Scholar
• Battise DM. Efficacy and safety of canagliflozin as add-on therapy to metformin in type 2 diabetes. Clin Diabetes 2014;32:81-6
   PubMedGoogle Scholar
• Garber AJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract 2017;23:207-38
   PubMed Web of Science ®Google Scholar
• Buysman EK, Chow W, Henk HJ. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin 2015;31:137-43
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter L, Yoon KH. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
   PubMed Web of Science ®Google Scholar
• Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016;18:82-91
   PubMed Web of Science ®Google Scholar
• Lavalle-González F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy A randomised trial. Diabetologia 2013;56:2582-2592
   PubMed Web of Science ®Google Scholar
• Meckley L, Miyasato G, Kokkotos F, et al. An Observational Study of Glycemic Control in Canagliflozin Treated Patients. Current Medical Research & Opinion 2014;7:1-23
   Google Scholar
• Nardolillo A, et al. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clinical medicine insights. Endocrinol Diabetes 2014;7:25
   Google Scholar
• Schernthaner G, Gross JL, Rosenstock J. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;372-82
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Pilon D, Robitaille MN, et al. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. Curr Med Res Opin 2016;1151-9
   PubMed Web of Science ®Google Scholar
• Wysham CH, Lefebvre P, Pilon D, et al. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. BMC endocrine disorders 2017;17:32
   PubMed Web of Science ®Google Scholar
• Thayer S, Chow W, Korrer S, et al. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087-96
   PubMed Web of Science ®Google Scholar
• National Conference of State Legislatures (NCSL). Diabetes health coverage: state laws and programs. Available online at: http://www.ncsl.org/research/health/diabetes-health-coverage-state-laws-and-programs.aspx#Florida. Accessed February 6, 2018
   Google Scholar
• Johnson JF, Parsa R, Bailey R. Real world clinical outcomes and patient characteristics for canagliflozin treated patients in a specialty diabetes clinic. Curr Med Res Opin 2017;33:77-84
   PubMed Web of Science ®Google Scholar
• Johnson JF, Parsa R, Bailey RA. Real-world clinical outcomes among patients with type 2 diabetes receiving canagliflozin at a specialty diabetes clinic: subgroup analysis by baseline HbA1c and age. Clin Ther 2017;39:1123-31
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol 2017;28:368-75
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, and Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:2099
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137-9
   PubMed Web of Science ®Google Scholar
• Blonde L, Woo V, Mathieu C, et al. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin 2015;31:1993-2000
   PubMed Web of Science ®Google Scholar
• Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010;123:S3-S11
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64
   PubMed Web of Science ®Google Scholar
• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-82
   PubMed Web of Science ®Google Scholar
• Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
   PubMed Web of Science ®Google Scholar
• Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014;14:37
   PubMed Web of Science ®Google Scholar
• Patrick Lefebvre WC, Pilon D, Emond B, et al. Real-world impact of canagliflozin on glycemic control, body weight, and blood pressure in Whites and African Americans with type 2 diabetes mellitus. In 76th Scientific Session of the American Diabetes Association. 2016. New Orleans June 10-14, 2016
   Google Scholar
• Gavin JR, 3rd, Davies MJ, Davies M, et al. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin 2015;31:1693-702
   PubMed Web of Science ®Google Scholar